Prioritization of Iranian Male Mental Disorders Based on latest Prevalence, Burden, Male/Female Ratio and Expert Pane; a Systematic Review
Men's Health Journal,
Vol. 5 No. 1 (2021),
6 January 2021
Introduction: Mental disorders are the most prevalent health problems in the world. 23.6\% of Iranians have at least one psychological disorder. Men usually neglect their mental health issues, and their top priority mental health disorders should be determined for health planning. Methods: International databases including MedLine, Scopus, Web of Science, ProQuest, and SID national database were searched from 2015 to October 2020. The latest reported prevalence and percent of total DALY (Disability-adjusted life year), their difference between sexes as well as the expert panel’s opinion about mental disorders were gathered in a matrix based on the Three-Dimensional Combined Approach Matrix (3D-CAM). Each item got a rank and prioritization was made base on mean rank. Results: Eight studies were included. The most prevalent mental disorders among the Iranian male population were Major Anxiety Disorders (MADs, 12\%) and the highest burden belonged to Major depressive disorder (MDD) comprising 2.88\% of the total DALY. Considering all parameters, the highest priority was the Drug Use Disorders (DUD) followed by Alcohol Use disorders (AUDs), Conduct disorder, MADs, Bipolar disorder, MDD, and Schizophrenia, respectively. Conclusion: Men are extremely affected by drug and alcohol use disorders in Iran and also there is a lack of practical screening and effective interventional programs for these disorders in the primary health care system. More intensive harm reduction programs are needed for decreasing devastating consequences of any substance use disorders as well as improving mental health literacy and raising awareness toward risk perception for preventive and controlling purposes.
- Mental disorders
- Disease burden
- Health priorities
How to Cite
2. Mirzaei M, Ardekani SMY, Mirzaei M, Dehghani A. Prevalence of depression, anxiety and stress among adult population: results of yazd health study. Iranian journal of psychiatry. 2019;14(2):137.
3. Charlson F, van Ommeren M, Flaxman A, Cornett J, Whiteford H, Saxena S. New WHO prevalence estimates of mental disorders in conflict settings: a systematic review and meta-analysis. The Lancet. 2019;394(10194):240-8.
4. Sharifi V, Amin-Esmaeili M, Hajebi A, Motevalian A, Radgoodarzi R, Hefazi M, et al. Twelve-month prevalence and correlates of psychiatric disorders in Iran: the Iranian Mental Health Survey, 2011. Archives of Iranian medicine. 2015;18(2):0-.
5. Amati F, Banks C, Greenfield G, Green J. Predictors of outcomes for patients with common mental health disorders receiving psychological therapies in community settings: a systematic review. Journal of Public Health. 2018;40(3):e375-e87.
6. Noorbala AA, Faghihzadeh S, Kamali K, Yazdi SAB, Hajebi A, Mousavi MT, et al. Mental health survey of the Iranian adult population in 2015. Archives of Iranian medicine. 2017;20(3):0-.
7. Plana-Ripoll O, Pedersen CB, Holtz Y, Benros ME, Dalsgaard S, De Jonge P, et al. Exploring comorbidity within mental disorders among a Danish national population. JAMA psychiatry. 2019;76(3):259-70.
8. Merikangas KR, Kalaydjian A. Magnitude and impact of comorbidity of mental disorders from epidemiologic surveys. Current Opinion in Psychiatry. 2007;20(4):353-8.
9. Anderson P, O'Donnell A, Kaner E, Gual A, Schulte B, Gómez AP, et al. Scaling-up primary health care-based prevention and management of heavy drinking at the municipal level in middle-income countries in Latin America: Background and protocol for a three-country quasi-experimental study. F1000Research. 2017;6.
10. Mackenzie CS, Visperas A, Ogrodniczuk JS, Oliffe JL, Nurmi MA. Age and sex differences in self-stigma and public stigma concerning depression and suicide in men. Stigma and Health. 2019;4(2):233.
11. Montorzi G, De Haan S, IJsselmuiden C. Priority Setting for Research for Health: a management process for countries. Geneva: Council on Health Research for Development (COHRED). 2010.
12. Gharraee B, Tajrishi KZ, Sheybani F, Tahmasbi N, Mirzaei M, Farahani H, et al. Prevalence of major depressive disorder in the general population of Iran: A systematic review and meta-analysis. Medical Journal of the Islamic Republic of Iran. 2019;33:151.
13. Hajebi A, Motevalian SA, Rahimi-Movaghar A, Sharifi V, Amin-Esmaeili M, Radgoodarzi R, et al. Major anxiety disorders in Iran: prevalence, sociodemographic correlates and service utilization. BMC psychiatry. 2018;18(1):1-8.
14. Amin-Esmaeili M, Rahimi-Movaghar A, Sharifi V, Hajebi A, Mojtabai R, Radgoodarzi R, et al. Alcohol use disorders in Iran: Prevalence, symptoms, correlates, and comorbidity. Drug and alcohol dependence. 2017;176:48-54.
15. Amin‐Esmaeili M, Rahimi‐Movaghar A, Sharifi V, Hajebi A, Radgoodarzi R, Mojtabai R, et al. Epidemiology of illicit drug use disorders in Iran: prevalence, correlates, comorbidity and service utilization results from the Iranian Mental Health Survey. Addiction. 2016;111(10):1836-47.
16. Salmanian M, Mohammadi MR, Hooshyari Z, Mostafavi SA, Zarafshan H, Khaleghi A, et al. Prevalence, comorbidities, and sociodemographic predictors of conduct disorder: the national epidemiology of Iranian children and adolescents psychiatric disorders (IRCAP). European child & adolescent psychiatry. 2019:1-15.
17. Charlson FJ, Ferrari AJ, Santomauro DF, Diminic S, Stockings E, Scott JG, et al. Global epidemiology and burden of schizophrenia: findings from the global burden of disease study 2016. Schizophrenia bulletin. 2018;44(6):1195-203.
18. Charara R, Forouzanfar M, Naghavi M, Moradi-Lakeh M, Afshin A, Vos T, et al. The burden of mental disorders in the eastern Mediterranean region, 1990-2013. PloS one. 2017;12(1):e0169575.
19. IHME. global burden of diseaase institute of health metrics and evaluation 2019 [Available from: https://vizhub.healthdata.org/gbd-compare/.
20. McHugh RK, Votaw VR, Sugarman DE, Greenfield SF. Sex and gender differences in substance use disorders. Clinical psychology review. 2018;66:12-23.
21. Carvalho AF, Heilig M, Perez A, Probst C, Rehm J. Alcohol use disorders. The Lancet. 2019;394(10200):781-92.
22. Al-Ansari B, Thow AM, Mirzaie M, Day CA, Conigrave KM. Alcohol policy in Iran: Policy content analysis. Int J Drug Policy. 2019;73:185-98.
23. Erskine HE, Ferrari AJ, Nelson P, Polanczyk GV, Flaxman AD, Vos T, et al. Research Review: Epidemiological modelling of attention‐deficit/hyperactivity disorder and conduct disorder for the Global Burden of Disease Study 2010. Journal of Child Psychology and Psychiatry. 2013;54(12):1263-74.
24. Moore AA, Silberg JL, Roberson-Nay R, Mezuk B. Life course persistent and adolescence limited conduct disorder in a nationally representative US sample: prevalence, predictors, and outcomes. Social psychiatry and psychiatric epidemiology. 2017;52(4):435-43.
25. Murray J, Farrington DP. Risk factors for conduct disorder and delinquency: key findings from longitudinal studies. The Canadian Journal of Psychiatry. 2010;55(10):633-42.
26. Carvalho AF, Firth J, Vieta E. Bipolar disorder. New England Journal of Medicine. 2020;383(1):58-66.
27. Marder SR, Cannon TD. Schizophrenia. The New England journal of medicine. 2019;381(18):1753-61.
- Abstract Viewed: 17 times
- pdf Downloaded: 19 times